InvestorsHub Logo
Followers 3
Posts 281
Boards Moderated 0
Alias Born 12/21/2022

Re: None

Friday, 03/29/2024 9:02:15 AM

Friday, March 29, 2024 9:02:15 AM

Post# of 608
Just published, "Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (mIDH1) acute myeloid leukemia (AML)". The results of this phase 2 study support data from registrational cohort demonstrating that Olutasidenib works well in patients previously treated with venetoclax.
https://pubmed.ncbi.nlm.nih.gov/38538632/
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent RIGL News